Aclaris Therapeutics, Inc.
https://www.aclaristx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aclaris Therapeutics, Inc.
Finance Watch: Janux Offering Makes 47 Biopharma IPOs In 2021, So Far
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
US FDA’s Rx Drug Promo Study Answers $798,000 Question
Viewers spend more time on print ads that have more lengthy important safety information or a brief summary but impact on understanding is unclear, OPDP study finds. Another study finds exaggerated images of drug benefits in TV ads unsurprisingly can mislead consumers.
Keeping Up With the Kardashians: US FDA Objects To Khloé’s Migraine Drug Promo
Agency cites video promoting Biohaven’s Nurtec ODT, which first aired on ABC’s TV show The View, for misleading comparative claims, inadequate display of risk information, and failure to submit promo for review.
Investors Animated Over Aclaris Oral Rheumatoid Arthritis Therapy
Great progress has been made in the treatment of RA with biologics and JAK inhibitors but there is a space for effective small-molecule therapies and Aclaris hopes to fill it with ATI-450.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Biotechnology
- Drug Discovery Tools
-
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
-
- Confluence Pharmaceuticals, LLC
- Confluence Discovery Technologies, Inc.